Mwanzo4DX • ASX
add
4DMedical Ltd
Bei iliyotangulia
$ 0.28
Bei za siku
$ 0.28 - $ 0.29
Bei za mwaka
$ 0.23 - $ 0.72
Thamani ya kampuni katika soko
128.37M AUD
Wastani wa hisa zilizouzwa
elfu 948.52
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
ASX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(AUD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 1.45M | 265.33% |
Matumizi ya uendeshaji wa biashara | 13.10M | 7.86% |
Mapato halisi | -9.58M | -22.82% |
Kiwango cha faida halisi | -662.04 | 66.38% |
Mapato kwa kila hisa | — | — |
EBITDA | -11.23M | -1.87% |
Asilimia ya kodi ya mapato | -0.04% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(AUD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 15.95M | -66.68% |
Jumla ya mali | 102.01M | -29.03% |
Jumla ya dhima | 42.15M | -19.87% |
Jumla ya hisa | 59.86M | — |
hisa zilizosalia | 413.32M | — |
Uwiano wa bei na thamani | 2.04 | — |
Faida inayotokana na mali | -28.80% | — |
Faida inayotokana mtaji | -45.42% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(AUD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -9.58M | -22.82% |
Pesa kutokana na shughuli | -7.07M | 4.01% |
Pesa kutokana na uwekezaji | elfu -422.55 | 97.85% |
Pesa kutokana na ufadhili | elfu 170.01 | -98.95% |
Mabadiliko halisi ya pesa taslimu | -7.33M | 32.46% |
Mtiririko huru wa pesa | -6.17M | 4.49% |
Kuhusu
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2013
Tovuti
Wafanyakazi
145